CHD Stock Analysis: Church & Dwight | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 25.805m USD | 12M Return: 32.7% | US1713401024 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 226M
EPS Trend: 95.0%
Qual. Beats: 0
Rev. Trend: 96.0%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Church & Dwight Co., Inc. (NYSE: CHD) develops, manufactures, and markets household, personal care, and specialty products across three reporting segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company sells its consumer goods through supermarkets, mass merchandisers, drugstores, e-commerce channels, and other retail outlets, while specialty products are sold to industrial customers and livestock producers via distributors.
Church & Dwight operates a brand-driven, multi-category portfolio within the consumer staples sector, leveraging flagship names such as ARM & HAMMER, OXICLEAN, WATERPIK, THERABREATH, BATISTE, TROJAN, FIRST RESPONSE, NAIR, ORAJEL, XTRA, ZICAM, HERO, and TOUCHLAND to address everyday household, personal care, and health needs. The company also offers animal nutrition and productivity products-including BIO-CHLOR, FERMENTEN, CELMANAX, and CERTILLUS-used across the poultry, dairy, beef, and swine industries, giving it a niche B2B livestock feed-additives business alongside its consumer-facing operations.
Founded in 1846 and headquartered in Ewing, New Jersey, Church & Dwight is a large-cap household products company that has been publicly traded since 1986. Its model is characteristic of the broader household products sub-industry, where large packaged-goods firms use extensive brand portfolios and broad retail distribution to generate relatively stable, repeat-purchase revenue streams.
- -driven organic sales growth in household and personal care
- TROJAN and WATERPIK personal care outpaces household segment growth
- Acquisition pipeline expands premium oral care and wellness portfolio
| Net Income: 774.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 0.15 > 1.0 |
| NWC/Revenue: -1.27% < 20% (prev 2.11%; Δ -3.38% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.20b > Net Income 774.8m |
| Net Debt (1.76b) to EBITDA (1.29b): 1.37 < 3 |
| Current Ratio: 0.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (238.7m) vs 12m ago -2.93% < -2% |
| Gross Margin: 46.09% > 18% (prev 44.44%; Δ 1.65% > 0.5%) |
| Asset Turnover: 67.58% > 50% (prev 67.16%; Δ 0.43% > 0%) |
| Interest Coverage Ratio: 10.89 > 6 (EBIT TTM 1.04b / Interest Expense TTM 95.2m) |
| A: -0.01 (Total Current Assets 1.77b - Total Current Liabilities 1.85b) / Total Assets 9.34b |
| B: 0.77 (Retained Earnings 7.18b / Total Assets 9.34b) |
| C: 0.11 (EBIT TTM 1.04b / Avg Total Assets 9.24b) |
| D: 0.92 (Book Value of Equity 4.48b / Total Liabilities 4.85b) |
| Altman-Z'' = 4.17 = AA |
| DSRI: 1.03 (Receivables 635.2m/605.7m, Revenue 6.25b/6.14b) |
| GMI: 0.96 (GM 44.44% / 46.09%) |
| AQI: 1.00 (AQ_t 0.72 / AQ_t-1 0.72) |
| SGI: 1.02 (Revenue 6.25b / 6.14b) |
| TATA: -0.05 (NI 774.8m - CFO 1.20b) / TA 9.34b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of November 12, 2026, the stock is trading at USD 112.02 with a total of 1,832,804 shares traded. Over the past week, the price has changed by -0.01%, over one month by +12.17%, over three months by +9.32% and over the past year by +32.70%.
Current recommended Stop Loss: 108.30 (which is 3.3% or 1.4 ATR below the current price).
Church & Dwight has received a consensus analysts rating of 3.71. Therefore, it is recommended to hold CHD.
- StrongBuy: 8
- Buy: 2
- Hold: 9
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 109 | -2.7% |
P/E Trailing = 33.5368
P/E Forward = 27.3224
P/S = 4.1318
P/B = 5.8603
P/EG = 3.1223
Revenue TTM = 6.25b USD
EBIT TTM = 1.04b USD
EBITDA TTM = 1.29b USD
Long Term Debt = 1.78b USD (from longTermDebt, last quarter)
Short Term Debt = 424.7m USD (from shortTermDebt, last quarter)
Debt = 2.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.76b USD (calculated: Debt 2.21b - CCE 446.9m)
Enterprise Value = 27.6b USD (25.8b + Debt 2.21b - CCE 446.9m)
Interest Coverage Ratio = 10.89 (Ebit TTM 1.04b / Interest Expense TTM 95.2m)
EV/FCF = 26.06x (Enterprise Value 27.6b / FCF TTM 1.06b)
FCF Yield = 3.84% (FCF TTM 1.06b / Enterprise Value 27.6b)
FCF Margin = 16.94% (FCF TTM 1.06b / Revenue TTM 6.25b)
Net Margin = 12.41% (Net Income TTM 774.8m / Revenue TTM 6.25b)
Gross Margin = 46.09% ((Revenue TTM 6.25b - Cost of Revenue TTM 3.37b) / Revenue TTM)
Gross Margin QoQ = 46.78% (prev 45.35%)
Tobins Q-Ratio = 2.95 (Enterprise Value 27.6b / Total Assets 9.34b)
Interest Expense / Debt = 4.31% (Interest Expense 95.2m / Debt 2.21b)
Taxrate = 21.62% (213.7m / 988.5m)
NOPAT = 812.9m (EBIT 1.04b * (1 - 21.62%))
Current Ratio = 0.96 (Total Current Assets 1.77b / Total Current Liabilities 1.85b)
Debt / Equity = 0.49 (Debt 2.21b / totalStockholderEquity, last quarter 4.48b)
Debt / EBITDA = 1.37 (Net Debt 1.76b / EBITDA 1.29b)
Debt / FCF = 1.66 (Net Debt 1.76b / FCF TTM 1.06b)
Total Stockholder Equity = 4.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.38% (Net Income 774.8m / Total Assets 9.34b)
RoE = 18.21% (Net Income TTM 774.8m / Total Stockholder Equity 4.25b)
RoCE = 17.18% (EBIT 1.04b / Capital Employed (Equity 4.25b + L.T.Debt 1.78b))
RoIC = 10.70% (NOPAT 812.9m / Invested Capital 7.60b)
WACC = 5.05% (E(25.8b)/V(28.0b) * Re(5.19%) + D(2.21b)/V(28.0b) * Rd(4.31%) * (1-Tc(0.22)))
Discount Rate = 5.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.80 | Cagr: -1.51%
[DCF] Terminal Value 75.89% ; FCFF base≈1.04b ; Y1≈1.08b ; Y5≈1.21b
[DCF] Fair Price = 71.70 (EV 18.7b - Net Debt 1.76b = Equity 16.9b / Shares 236.0m; r=8.35% [WACC [floored]]; 5y FCF grow 3.45% → 2.50% )
EPS Correlation: 94.99 | EPS CAGR: 4.24% | SUE: 0.48 | # QB: 0
Revenue Correlation: 96.03 | Revenue CAGR: 2.10% | SUE: 0.82 | # QB: 0
EPS current Quarter (2027-03-31): EPS=1.01 | Chg30d=+0.52% | Revisions=+0% | Analysts=12
EPS current Year (2026-12-31): EPS=3.77 | Chg30d=+0.08% | Revisions=+22% | GrowthEPS=+6.9% | GrowthRev=+0.7%
EPS next Year (2027-12-31): EPS=4.05 | Chg30d=+0.47% | Revisions=+0% | GrowthEPS=+7.4% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: +12% (up=8, down=6)